On December 9, 2019 Medicenna Therapeutics Corp. ("Medicenna" or "the Company") (TSX: MDNA,OTCQB: MDNAF), a clinical stage immuno-oncology company, reported that it will present results from the Phase 2b clinical trial of MDNA55 for the treatment of recurrent glioblastoma (rGBM) at the Inaugural Glioblastoma Drug Development Annual Summit to be held on December 10 and 11 at the Westin Boston Waterfront Hotel in Boston, Massachusetts (Press release, Medicenna Therapeutics, DEC 9, 2019, View Source [SID1234552166]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The oral presentation will provide details on survival seen in patients with rGBM from the MDNA55 Phase 2b clinical trial, including trends observed in different population subgroups.

The details of the presentation are as follows:

Title:

Clinical Case Study: Using a Multi-pronged Approach to Treating Recurrent GBM

– Overcoming the Tumor and its Microenvironment

Presenter:

Dr. Fahar Merchant, PhD, President and CEO of Medicenna Therapeutics

Date/Time:

Wednesday, December 11, 2019 at 10:30 AM ET

Location:

Westin Boston Waterfront Hotel, 425 Summer Street, Boston

In addition, Medicenna will be presenting at the 12th Annual LD Micro Main Event Investor Conference taking place at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Ms. Elizabeth Williams, Medicenna’s CFO is scheduled to present on Tuesday, December 10, 2019 at 3:20 p.m. Pacific Time and will be available for one-on-one meetings on December 10th and 11th.